Search
APL-030
go.drugbank.com/drugs/DB18735ExperimentalAPL-030 is a orally-active small molecule inhibitor of GCN2.
Synonyms: N-(4-((2-aminopyrimidin-5-yl)ethynyl)-3-fluoropyridin-2-yl)-5-chloro-2-methoxypyridine-3-sulfonamideBA1301
go.drugbank.com/drugs/DB19390InvestigationalBA1301 is an anti-Claudin18.2 monoclonal antibody conjugated with Duostatin-5.
YMI024
go.drugbank.com/drugs/DB32602ExperimentalYMI024 is a drug being investigated for inflammation-driven diseases.[L56081]
MB07811
go.drugbank.com/drugs/DB05192InvestigationalMB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides.
RGN6024
go.drugbank.com/drugs/DB33059ExperimentalRGN6024, also known as RGN-6024 or RGNi6024, is a synthetic small-molecule tubulin destabilizer from Reglagene. … RGN6024 remains investigational and is not an approved drug.
AICA ribonucleotide
go.drugbank.com/drugs/DB01700Investigational5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is an intermediate in the generation of inosine monophosphate and analog of adenosine monophosphate (AMP) that is capable of stimulating AMP-dependent … The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity
Synonyms: 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide, 1-(5'-phosphoribosyl)-5-amino-4-imidazolecarboxamideCategories: Heterocyclic Compounds, 1-RingTM30339
go.drugbank.com/drugs/DB05085ExperimentalTM30339 thus imitates a natural mechanism, a satiety signal from the gastrointestinal system involved in the regulation of food intake in humans. TM30339 is developed for the treatment of obesity. … TM30339 is an analogue of the natural hormone Pancreatic Polypeptide (PP), which is released in connection with meals.
SCB-2019
go.drugbank.com/drugs/DB15805InvestigationalSCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. … As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.
Brilaroxazine
go.drugbank.com/drugs/DB09226InvestigationalBrilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. … As of May 2015, it is in phase III clinical trials for schizophrenia.
Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2C Receptor AntagonistsSynonyms: 6-(4-(4-(2,3-Dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo(b)(1,4)oxazin-3(4H)-oneLotiglipron
go.drugbank.com/drugs/DB21631InvestigationalLotiglipron is a small molecule drug. The usage of the INN stem '-glipron' in the name indicates that Lotiglipron is a glucagon-like peptide 1 receptor (GLPIR) agonist. … Lotiglipron is under investigation in clinical trial NCT05579977 (Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People